Atopic dermatitis
Conditions
Interventions
In addition to the usual treatment(topical medicine), use the tested product.
In addition to the usual treatment(topical medicine), use the placebo.
Sponsors
Mie University, Graduate School of Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1)Persons with severe or moderate disease severity classification defined by atopic dermatitis Japanese Dermatological Association. 2)18 years of age or older (at the time of obtaining informed consent) 3)Unquestioned gender. 4)Outpatient 5)Persons with voluntary documented consent form. 6)Who with night itching.
Exclusion criteria
Exclusion criteria: 1)Those who may be pregnant or possible pregnant. 2)Those who have critical renal dysfunction and an impaired liver function. 3)The person under the specific or nonspecific de-sensitization treatment. 4)Those who took or injected a steroid, methotrexate, and cyclosporin in two weeks of the test . 5)Those who took the antihistamine within one week before the trial. 6)Those who have been engaged in business, such as operation of the car or machine. 7)The patient who is under the treatment of PUVA therapy using photo-senstive pills. 8)The patient with hypersensitivity or a drug-induced organ injury in the past with the use of Olopatadine, such as a Olopatadine hydrochloride (areroc(R)) and eye-drops Patanol (R). 9)Have lactose intolerance. 10)The person who is unsuitable for the entry judged by a doctor.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Measurement of the scratching ratio and depth of the sleep. The measurement will be performed on the day -2, -1 and 7 for atopic dermatitis patients. The measurement on day 7 day can be extended up to other 3 days, in case the subject is not available on day7. The VAS value of itch and the dermatitis score (EASI,ELQI) are measured for atopic dermatitis patient. Medication and the measurement on day 7 will not be performed for the healthy individuals. | — |
Countries
Japan
Outcome results
None listed